New answer by Medical Oncologist at University of Michigan Medical School (August 24, 2021)
R776H is a rare exon 20 point mutation. Preclinical models suggest that it is an activating mutation and that it is sensitive to erlotinib, afatinib, and osimertinib [Kohsaka ...